Skip to main content
Top
Published in: Annals of General Psychiatry 1/2017

Open Access 01-12-2017 | Case report

Amisulpride withdrawal dyskinesia: a case report

Authors: Yu-Chi Lo, Ying-Chieh Peng

Published in: Annals of General Psychiatry | Issue 1/2017

Login to get access

Abstract

Background

The effects of antipsychotic drug withdrawal have been inadequately studied. Case reports have described dyskinesia occurring in patients with several antipsychotics withdrawn, but studies on amisulpride withdrawal dyskinesia are lacking.

Case presentation

A 63-year-old man, who was diagnosed with schizophrenia at age 49, received amisulpride treatment since age 62. The dosage of amisulpride was reduced from 200 to 50 mg/day because of occurrence of akathisia during one admission. Severe withdrawal dyskinesia, mixed with dystonia and akathisia, was noted immediately after the dosage reduction. The abnormal involuntary movement showed improvement 2 weeks later when the dosage was increased to 100 mg/day.

Conclusions

Withdrawal dyskinesia and other abnormal involuntary movements could be noted in a patient with reduction of amisulpride dosage or sudden termination. Withdrawal dyskinesia may subsequently lead to persistent tardive dyskinesia. Therefore, withdrawal-emergent dyskinesia should be promptly identified, and appropriate medical interventions should be given early.
Appendix
Available only for authorised users
Literature
1.
go back to reference Salomon C, Hamilton B, Elsom S. Experiencing antipsychotic discontinuation: results from a survey of Australian consumers. J Psychiatr Ment Health Nurs. 2014;21:917–23.CrossRefPubMed Salomon C, Hamilton B, Elsom S. Experiencing antipsychotic discontinuation: results from a survey of Australian consumers. J Psychiatr Ment Health Nurs. 2014;21:917–23.CrossRefPubMed
2.
go back to reference Polizos P, Engelhardt DM, Hoffman SP, Waizer J. Neurological consequences of psychotropic drug withdrawal in schizophrenic children. J Autism Child Schizophr. 1973;3:247–53.CrossRefPubMed Polizos P, Engelhardt DM, Hoffman SP, Waizer J. Neurological consequences of psychotropic drug withdrawal in schizophrenic children. J Autism Child Schizophr. 1973;3:247–53.CrossRefPubMed
3.
go back to reference Gardos G, Cole JO, Tarsy D. Withdrawal syndromes associated with antipsychotic drugs. Am J Psychiatry. 1978;135:1321–4.CrossRefPubMed Gardos G, Cole JO, Tarsy D. Withdrawal syndromes associated with antipsychotic drugs. Am J Psychiatry. 1978;135:1321–4.CrossRefPubMed
4.
go back to reference Teo JT, Edwards MJ, Bhatia K. Tardive dyskinesia is caused by maladaptive synaptic plasticity: a hypothesis. Mov Disord. 2012;27:1205–15.CrossRefPubMed Teo JT, Edwards MJ, Bhatia K. Tardive dyskinesia is caused by maladaptive synaptic plasticity: a hypothesis. Mov Disord. 2012;27:1205–15.CrossRefPubMed
5.
go back to reference Thornton WE, Thornton BP. Tardive dyskinesias from the major tranquilizers. J Fla Med Assoc. 1973;60:24–6. Thornton WE, Thornton BP. Tardive dyskinesias from the major tranquilizers. J Fla Med Assoc. 1973;60:24–6.
8.
go back to reference Jacobson G, Baldessarini RI, Manschrek T. Tardive and withdrawal dyskinesia associated with haloperidol. Am J Psychiatry. 1974;131:910–3.PubMed Jacobson G, Baldessarini RI, Manschrek T. Tardive and withdrawal dyskinesia associated with haloperidol. Am J Psychiatry. 1974;131:910–3.PubMed
9.
go back to reference Alblowi MA, Alosaimi FD. Tardive dyskinesia occurring in a young woman after withdrawal of an atypical antipsychotic drug. Neurosciences. 2015;20:376–9.CrossRefPubMedPubMedCentral Alblowi MA, Alosaimi FD. Tardive dyskinesia occurring in a young woman after withdrawal of an atypical antipsychotic drug. Neurosciences. 2015;20:376–9.CrossRefPubMedPubMedCentral
10.
go back to reference Komatsu S, Kirino E, Inoue Y, Arai H. Risperidone withdrawal-related respiratory dyskinesia: a case diagnosed by spirography and fibroscopy. Clin Neuropharmacol. 2005;28:90–3.CrossRefPubMed Komatsu S, Kirino E, Inoue Y, Arai H. Risperidone withdrawal-related respiratory dyskinesia: a case diagnosed by spirography and fibroscopy. Clin Neuropharmacol. 2005;28:90–3.CrossRefPubMed
11.
go back to reference Anand VS, Dewan MJ. Withdrawal-emergent dyskinesia in a patient on risperidone undergoing dosage reduction. Ann Clin Psychiatry. 1996;8:179–82.CrossRefPubMed Anand VS, Dewan MJ. Withdrawal-emergent dyskinesia in a patient on risperidone undergoing dosage reduction. Ann Clin Psychiatry. 1996;8:179–82.CrossRefPubMed
12.
go back to reference Urbano M, Spiegel D, Rai A. Atypical antipsychotic withdrawal dyskinesia in 4 patients with mood disorders. J Clin Psychopharmacol. 2007;27:705–7.CrossRefPubMed Urbano M, Spiegel D, Rai A. Atypical antipsychotic withdrawal dyskinesia in 4 patients with mood disorders. J Clin Psychopharmacol. 2007;27:705–7.CrossRefPubMed
13.
go back to reference Philip NS. An aripiprazole discontinuation syndrome. R I Med J. 2013;96:13–4. Philip NS. An aripiprazole discontinuation syndrome. R I Med J. 2013;96:13–4.
14.
go back to reference Moseley CN, Simpson-Khanna HA, Catalano G, Catalano MC. Covert dyskinesia associated with aripiprazole: a case report and review of the literature. Clin Neuropharmacol. 2013;36:128–30.CrossRefPubMed Moseley CN, Simpson-Khanna HA, Catalano G, Catalano MC. Covert dyskinesia associated with aripiprazole: a case report and review of the literature. Clin Neuropharmacol. 2013;36:128–30.CrossRefPubMed
15.
go back to reference Ahmed S, Chengappa KN, Naidu VR, Baker RW, Parepally H, Schooler NR. Clozapine withdrawal-emergent dystonias and dyskinesias: a case series. J Clin Psychiatry. 1998;59:472–7.CrossRefPubMed Ahmed S, Chengappa KN, Naidu VR, Baker RW, Parepally H, Schooler NR. Clozapine withdrawal-emergent dystonias and dyskinesias: a case series. J Clin Psychiatry. 1998;59:472–7.CrossRefPubMed
16.
go back to reference Perényi A, Frecska E, Bagdy G, Révai K. Changes in mental condition, hyperkinesias and biochemical parameters after withdrawal of chronicneuroleptic treatment. Acta Psychiatr Scand. 1985;72:430–5.CrossRefPubMed Perényi A, Frecska E, Bagdy G, Révai K. Changes in mental condition, hyperkinesias and biochemical parameters after withdrawal of chronicneuroleptic treatment. Acta Psychiatr Scand. 1985;72:430–5.CrossRefPubMed
17.
go back to reference Kane JM, Woerner M, Lieberman J. Tardive dyskinesia: prevalence, incidence, and risk factors. J Clin Psychopharmacol. 1988;8:52S–6S.CrossRefPubMed Kane JM, Woerner M, Lieberman J. Tardive dyskinesia: prevalence, incidence, and risk factors. J Clin Psychopharmacol. 1988;8:52S–6S.CrossRefPubMed
18.
go back to reference Schultz SK, Miller DD, Arndt S, Ziebell S, Gupta S, Andreasen NC. Withdrawal-emergent dyskinesia in patients with schizophrenia during antipsychotic discontinuation. Biol Psychiatry. 1995;38:713–9.CrossRefPubMed Schultz SK, Miller DD, Arndt S, Ziebell S, Gupta S, Andreasen NC. Withdrawal-emergent dyskinesia in patients with schizophrenia during antipsychotic discontinuation. Biol Psychiatry. 1995;38:713–9.CrossRefPubMed
19.
go back to reference Emsley R, Turner HJ, Schronen J, Botha K, Smit R, Oosthuizen PP. A single-blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia. J Clin Psychiatry. 2004;65:696–701.CrossRefPubMed Emsley R, Turner HJ, Schronen J, Botha K, Smit R, Oosthuizen PP. A single-blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia. J Clin Psychiatry. 2004;65:696–701.CrossRefPubMed
20.
go back to reference Angus S, Sugars J, Boltezar R, Koskewich S, Schneider NM. A controlled trial of amantadine hydrochloride and neuroleptics in the treatment of tardive dyskinesia. J Clin Psychopharmacol. 1997;17:88–91.CrossRefPubMed Angus S, Sugars J, Boltezar R, Koskewich S, Schneider NM. A controlled trial of amantadine hydrochloride and neuroleptics in the treatment of tardive dyskinesia. J Clin Psychopharmacol. 1997;17:88–91.CrossRefPubMed
21.
go back to reference Thaker GK, Nguyen JA, Strauss ME, Jacobson R, Kaup BA, Tamminga CA. Clonazepam treatment of tardive dyskinesia: a practical GABAmimetic strategy. Am J Psychiatr. 1990;147:445–51.CrossRefPubMed Thaker GK, Nguyen JA, Strauss ME, Jacobson R, Kaup BA, Tamminga CA. Clonazepam treatment of tardive dyskinesia: a practical GABAmimetic strategy. Am J Psychiatr. 1990;147:445–51.CrossRefPubMed
22.
go back to reference Van Harten PN, Hoek HW, Matroos GE, van Os J. Evidence that lithium protects against tardive dyskinesia: the Curaçao Extrapyramidal syndromes study VI. Eur Neuropsychopharmacol. 2008;18:152–5.CrossRefPubMed Van Harten PN, Hoek HW, Matroos GE, van Os J. Evidence that lithium protects against tardive dyskinesia: the Curaçao Extrapyramidal syndromes study VI. Eur Neuropsychopharmacol. 2008;18:152–5.CrossRefPubMed
23.
go back to reference McGrath J, Soares-Weiser K. Vitamin E for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2011;16:000209. McGrath J, Soares-Weiser K. Vitamin E for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2011;16:000209.
24.
go back to reference Shamir E, Barak Y, Shalman I, Laudon M, Zisapel N, Tarrasch R, Elizur A, Weizman R. Melatonin treatment for tardive dyskinesia: a double-blind, placebo-controlled, crossover study. Arch GenPsychiatry. 2001;58:1049–52.CrossRef Shamir E, Barak Y, Shalman I, Laudon M, Zisapel N, Tarrasch R, Elizur A, Weizman R. Melatonin treatment for tardive dyskinesia: a double-blind, placebo-controlled, crossover study. Arch GenPsychiatry. 2001;58:1049–52.CrossRef
25.
go back to reference Waln O, Jankovic J. Zolpidem improves tardive dyskinesia and akathisia. Mov Disord. 2013;28:1748–9.CrossRefPubMed Waln O, Jankovic J. Zolpidem improves tardive dyskinesia and akathisia. Mov Disord. 2013;28:1748–9.CrossRefPubMed
Metadata
Title
Amisulpride withdrawal dyskinesia: a case report
Authors
Yu-Chi Lo
Ying-Chieh Peng
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Annals of General Psychiatry / Issue 1/2017
Electronic ISSN: 1744-859X
DOI
https://doi.org/10.1186/s12991-017-0148-0

Other articles of this Issue 1/2017

Annals of General Psychiatry 1/2017 Go to the issue